

Patient: Tom Williams,  
age 47, contractor\*

**CAN YOU I.D. THIS  
PATIENT'S PROBLEM?**

**Medical history** (Check all that apply):

- |   |   |
|---|---|
| <input type="checkbox"/> Heart disease                  | <input type="checkbox"/> Cancer               |
| <input checked="" type="checkbox"/> High blood pressure | <input checked="" type="checkbox"/> Hay fever |
| <input type="checkbox"/> Diabetes                       | <input checked="" type="checkbox"/> Heartburn |
| <input type="checkbox"/> Bleeding disorders             | <input type="checkbox"/> Asthma               |
| <input type="checkbox"/> Kidney disease                 |   |

**List medications you are currently taking:**

Antacid, Glucosamine


**Reason(s) for your visit today:**

*Sometimes burning discomfort in my chest wakes me up during the night and this disturbs my sleep. I wake up with a taste in my mouth like I've vomited. I'm not sleeping well, and it's making me late for work a lot.*

\*Simulated patient profile.

# When the Dx is erosive NIGHTTIME GERD, make the Rx PROTONIX 40 mg

PROTONIX 40 mg controlled NIGHTTIME GERD symptoms in two 12-month studies<sup>1-3</sup>



- PROTONIX Delayed-Release Tablets are indicated for the treatment and maintenance of healing of erosive esophagitis with associated gastroesophageal reflux disease (GERD) symptoms. Controlled studies did not extend beyond 12 months
- In clinical trials, the most frequently reported adverse events with PROTONIX Delayed-Release Tablets were headache, diarrhea, and flatulence. Symptomatic response to therapy does not preclude the presence of gastric malignancy. PROTONIX is contraindicated in patients with known hypersensitivity to any component of the formulation. Patients treated with PPIs and warfarin concomitantly should be monitored for increases in INR and prothrombin time

**Please see accompanying Prescribing Information.**

**References:** **1.** Richter JE, Fraga P, Mack M, et al. Prevention of erosive oesophagitis relapse with pantoprazole. *Aliment Pharmacol Ther.* 2004;20:567-575. **2.** Metz DC, Bochenek WJ, and the Pantoprazole US GERD Study Group. Pantoprazole maintenance therapy prevents relapse of erosive oesophagitis. *Aliment Pharmacol Ther.* 2003; 17:155-164. **3.** Data on file, Wyeth Pharmaceuticals Inc.

[www.PROTONIX.com](http://www.PROTONIX.com)



ONCE-A-DAY  
**PROTONIX**<sup>®</sup> **40mg**  
(pantoprazole sodium) Delayed-Release Tablets  
**RIGHT FOR THE NIGHT**

**Wyeth**<sup>®</sup> under license from  
ALTANA Pharma  
D78467 Konstanz, Germany

© 2006, Wyeth Pharmaceuticals Inc., Philadelphia, PA 19101

XXXXXX-XX

April 2006